4:21 PM
 | 
Sep 13, 2013
 |  BC Extra  |  Financial News

Regeneron jumps on analyst note, Viehbacher comments

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) added $16.37 to $289.97 on Friday on a note from RBC Capital highlighting Regeneron and the biotech's alirocumab ( REGN727), which is in the Phase III ODYSSEY...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >